Clinical Trials

A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Location:

Trial status:

Inactive

Why is this study being done?

The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule

Who is eligible to participate?

Inclusion Criteria:

- Advanced or metastatic cancer (excluding cancer in the blood) or uncontrolled basal cell nevoid syndrome or sporadic basal cell carcinoma

- Primary or metastatic tumor site accessible for biopsy

- Ability to swallow capsules

- Subjects with histologically confirmed, advanced stage IIIB or stage IV non-small cell lung cancer (NSCLC) with a primary histology of squamous carcinoma who have received prior systemic therapy for advanced NSCLC will be enrolled in Part 3

Exclusion Criteria:

- Uncontrolled brain metastasis

- Significant cardiovascular disease

- Inadequate blood counts

- Inadequate liver, kidney or lung function

- Gastrointestinal disease within last 3 months

- Infection with Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C or exposure to attenuated active immunizations

Last updated: 07/03/2012

NCT ID:

NCT00670189